A Phase 1 interventional study of PF-02341066 in Healthy Volunteer, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-29.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-02341066
oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of \[14C\]PF 02341066
Also known as: crizotinib
Maximum Observed Plasma Concentration (Cmax)
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours (hrs), 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast)
Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Plasma Decay Half Life (t1/2)
Plasma Decay half-life is the time measured for the concentration to decrease by one half.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Oral Clearance (CL/F) of Plasma PF-02341066
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Volume of Distribution (V/F) in Plasma
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Renal Clearance (CLr) of PF-02341066
CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.
Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae)
Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.
Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)]
Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Maximum Observed Concentration in Plasma Radioactivity (Cmax)
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax)
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast)
Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Plasma Radioactivity Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in plasma. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Decay Half Life (t1/2) of Radioactivity in Plasma
Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Oral Clearance (CL/F) of Plasma Radioactivity
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Volume of Distribution (V/F) in Plasma Radioactivity
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax)
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood
Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood
Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Radioactivity in Whole Blood
Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Decay Half-life (t1/2) of Radioactivity in Whole Blood
Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Oral Clearance of Radioactivity From Whole Blood (CL/F)
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Apparent Volume of Distribution of Radioactivity in Whole Blood (V/F)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Total [14C] Data in Urine
Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
Total [14C] Data in Feces
Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
Time frame: From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose
Overall Cumulative Percent Recovery of Radioactivity
Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
Time frame: Pre-dose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose for urine and Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose for feces
Identification and Profiling of Metabolites of [14C]PF-02341066 in Plasma
Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (\>=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
Time frame: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hrs, 36 hrs, 48 hrs, then after every 24 hrs until up to 480 hrs post-dose
Identification and Profiling of Metabolites of [14C]PF-02341066 in Feces
In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
Time frame: From Day 0 through pre-dose (Day1) and as passed through until up to 480 hrs post-dose
Identification and Profiling of Metabolites of [14C]PF-02341066 in Urine
In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
Time frame: Predose, 0 to 4, 4 to 8, 8 to 16, 16 to 24 to 36, 36 to 48 hrs and then after every 24 hrs until up to 480 hrs post-dose
| Milestone | PF-02341066 250 mg |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
| ng/mL | PF-02341066 250 mg |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 109.400 ± 54.153 |
| hr | PF-02341066 250 mg |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 2.99 (1.98 to 6.00) |
Area under the concentration time-curve from zero to the last measured plasma concentration (AUClast).
| ng*hr/mL | PF-02341066 250 mg |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) | 2686.0 ± 1119.6 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | PF-02341066 250 mg |
|---|---|
| Area Under the Plasma Concentration Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] | 2777.0 ± 1114.9 |
Plasma Decay half-life is the time measured for the concentration to decrease by one half.
| hr | PF-02341066 250 mg |
|---|---|
| Plasma Decay Half Life (t1/2) | 93.970 ± 13.797 |
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| L/hr | PF-02341066 250 mg |
|---|---|
| Apparent Oral Clearance (CL/F) of Plasma PF-02341066 | 90.140 ± 23.984 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.
| L | PF-02341066 250 mg |
|---|---|
| Apparent Volume of Distribution (V/F) in Plasma | 12110.0 ± 4544.5 |
CLr is the volume of plasma from which a substance is completely removed by the kidney in a given amount of time.
| L/hr | PF-02341066 250 mg |
|---|---|
| Renal Clearance (CLr) of PF-02341066 | 2.11 ± 0.29 |
Ae = concentration of unchanged drug excreted in the urine multiplied by volume of unchanged drug excreted in urine.
| mg | PF-02341066 250 mg |
|---|---|
| Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to Infinite Time (Ae) | 5.847 ± 3.450 |
| Percent dose of unchanged drug | PF-02341066 250 mg |
|---|---|
| Total Amount of Unchanged Drug Excreted in the Urine Expressed as Percent of Dose From Time Zero to Infinite Time [Ae(%)] | 2.339 ± 1.380 |
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| nanogram-equivalent/milliliter(ng-eq/mL) | PF-02341066 250 mg |
|---|---|
| Maximum Observed Concentration in Plasma Radioactivity (Cmax) | 435.600 ± 82.072 |
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| hr | PF-02341066 250 mg |
|---|---|
| Time to Reach Maximum Observed Plasma Radioactivity Concentration (Tmax) | 5.00 (2.98 to 6.00) |
Area under the concentration time-curve from zero to the last measured plasma concentration. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| ng-eq*hr/mL | PF-02341066 250 mg |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Plasma Radioactivity Concentration (AUClast) | 22830.0 ± 2636.4 |
Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in plasma. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Plasma decay half-life is the time measured for the plasma radioactivity concentration to decrease by one half. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| ng-eq/mL | PF-02341066 250 mg |
|---|---|
| Maximum Observed Concentration of Radioactivity in Whole Blood (Cmax) | 312.300 ± 62.669 |
Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| hr | PF-02341066 250 mg |
|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) of Radioactivity in Whole Blood | 4.00 (2.98 to 6.00) |
Area under the concentration time-curve from zero to the last measured concentration (AUClast) in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
| ng-eq*hr/mL | PF-02341066 250 mg |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Radioactivity in Whole Blood | 7032.0 ± 1284.2 |
Area under the concentration curve from time zero to extrapolated infinite time \[AUC (0 - ∞)\] in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Decay half life (t1/2) is the time measured for the concentration to decrease by one half in whole blood. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed. Radioactivity corresponds to 100 μCi \[14C\]PF-02341066.
No measurements were reported for this outcome.
Cumulative amount excreted in urine at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
| ng-eq | PF-02341066 250 mg |
|---|---|
| Total [14C] Data in Urine | 56200000 ± 11500000 |
Cumulative amount excreted in feces at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
| ng-eq | PF-02341066 250 mg |
|---|---|
| Total [14C] Data in Feces | 160000000 ± 15000000 |
Overall cumulative percent of radioactive dose recovered in urine, feces and toilet tissue at specified intervals after administration of a single 250-mg (100 μCi) oral dose of \[14C\]PF-02341066.
| Percent recovery of radioactivity | PF-02341066 250 mg |
|---|---|
| Urine | 22.20 ± 4.63 |
| Feces | 63.10 ± 5.93 |
| Overall | 85.20 ± 8.38 |
Identification was done by Radio-High Performance liquid chromatography (HPLC) chromatogram. Relative abundance (profiling) of metabolites in chromatogram were determined by dividing sum of radioactive content of fractions contributing to particular peak by sum of radioactive content of all fractions constructing the radio chromatogram. Metabolites accounting for an average of greater than or equal to (\>=) 10% of total recoverable radioactivity in plasma were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
| Percentage of recovered radioactivity | PF-02341066 250 mg |
|---|---|
| PF-02341066 | 33.1 |
| M10, PF-06260182 | 10.2 |
In feces, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
| Percentage of radioactive dose | PF-02341066 250 mg |
|---|---|
| PF-02341066 | 53.5 |
| M8 | NA |
In urine, metabolite abundance (profiling) was calculated by multiplying the fractional contribution of radioactive response for the peak in the Radio-HPLC chromatogram to the total radioactivity detected by the percent of administered dose recovered in the matrix. Only those metabolites that were a component of a chromatographic peak that accounted for an average of \>=1% of the administered dose, were summarized. Radioactivity corresponds to 100 μCi \[14C\] PF-02341066.
| Percentage of radioactive dose | PF-02341066 250 mg |
|---|---|
| PF-02341066 | 2.4 |
| M8 | 4.5 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-02341066 250 mg | — | 0/6 (0%) | 6/6 (100%) |
| Event | PF-02341066 250 mg |
|---|---|
| DiarrhoeaGastrointestinal disorders | 4/6 |
| Abdominal discomfortGastrointestinal disorders | 1/6 |
| Abdominal pain upperGastrointestinal disorders | 1/6 |
| ConstipationGastrointestinal disorders | 1/6 |
| DyspepsiaGastrointestinal disorders | 1/6 |
| SomnolenceNervous system disorders | 1/6 |
| Seborrhoeic dermatitisSkin and subcutaneous tissue disorders | 1/6 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/6 |
| Age Continuous(years) | PF-02341066 250 mg |
|---|---|
| Mean | 43.2 ± 1.8 |
| Sex: Female, Male(Participants) | PF-02341066 250 mg |
|---|---|
| Female | 0 |
| Male | 6 |
The record gives a start of Mar 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crizotinib